These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 35838992)

  • 1. Methylation of PCDH17 and NEFH as prognostic biomarker for nonmetastatic RCC: A cohort study.
    Koudonas A; Papaioannou M; Kampantais S; Anastasiadis A; Hatzimouratidis K; Dimitriadis G
    Medicine (Baltimore); 2022 Jul; 101(28):e29599. PubMed ID: 35838992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a prognostic risk model for clear cell renal cell carcinoma by systematic evaluation of DNA methylation markers.
    Joosten SC; Odeh SNO; Koch A; Buekers N; Aarts MJB; Baldewijns MMLL; Van Neste L; van Kuijk S; Schouten LJ; van den Brandt PA; Tjan-Heijnen VC; van Engeland M; Smits KM
    Clin Epigenetics; 2021 May; 13(1):103. PubMed ID: 33947447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant Promoter Methylation of PCDH17 (Protocadherin 17) in Serum and its Clinical Significance in Renal Cell Carcinoma.
    Lin YL; Wang YP; Li HZ; Zhang X
    Med Sci Monit; 2017 Jul; 23():3318-3323. PubMed ID: 28688232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protocadherin17 Promoter Methylation is a Potential Predictive Biomarker in Clear Cell Renal Cell Carcinoma.
    Lin YL; Gui SL; Guo H; Ma JG; Li WP
    Med Sci Monit; 2015 Sep; 21():2870-6. PubMed ID: 26404644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurofilament Heavy polypeptide CpG island methylation associates with prognosis of renal cell carcinoma and prediction of antivascular endothelial growth factor therapy response.
    Dubrowinskaja N; Gebauer K; Peters I; Hennenlotter J; Abbas M; Scherer R; Tezval H; Merseburger AS; Stenzl A; Grünwald V; Kuczyk MA; Serth J
    Cancer Med; 2014 Apr; 3(2):300-9. PubMed ID: 24464810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Four-Gene Promoter Methylation Marker Panel Consisting of
    van Vlodrop IJH; Joosten SC; De Meyer T; Smits KM; Van Neste L; Melotte V; Baldewijns MMLL; Schouten LJ; van den Brandt PA; Jeschke J; Yi JM; Schuebel KE; Ahuja N; Herman JG; Aarts MJ; Bosman FT; Van Criekinge W; van Engeland M
    Clin Cancer Res; 2017 Apr; 23(8):2006-2018. PubMed ID: 27756787
    [No Abstract]   [Full Text] [Related]  

  • 7. Prognostic significance of promoter CpG island methylation of obesity-related genes in patients with nonmetastatic renal cell carcinoma.
    Mendoza-Pérez J; Gu J; Herrera LA; Tannir NM; Zhang S; Matin S; Karam JA; Wood CG; Wu X
    Cancer; 2017 Sep; 123(18):3617-3627. PubMed ID: 28543182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant methylation of protocadherin 17 and its clinical significance in patients with prostate cancer after radical prostatectomy.
    Lin YL; Xie PG; Wang L; Ma JG
    Med Sci Monit; 2014 Aug; 20():1376-82. PubMed ID: 25091018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA methylation of neural EGFL like 1 (NELL1) is associated with advanced disease and the metastatic state of renal cell cancer patients.
    Peters I; Dubrowinskaja N; Hennenlotter J; Antonopoulos WI; Von Klot CAJ; Tezval H; Stenzl A; Kuczyk MA; Serth J
    Oncol Rep; 2018 Dec; 40(6):3861-3868. PubMed ID: 30272321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
    Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
    Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RASSF1A promoter hypermethylation is a strong biomarker of poor survival in patients with salivary adenoid cystic carcinoma in a Chinese population.
    Zhang CY; Zhao YX; Xia RH; Han J; Wang BS; Tian Z; Wang LZ; Hu YH; Li J
    PLoS One; 2014; 9(10):e110159. PubMed ID: 25302792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GATA5 CpG island methylation in renal cell cancer: a potential biomarker for metastasis and disease progression.
    Peters I; Eggers H; Atschekzei F; Hennenlotter J; Waalkes S; Tränkenschuh W; Grosshennig A; Merseburger AS; Stenzl A; Kuczyk MA; Serth J
    BJU Int; 2012 Jul; 110(2 Pt 2):E144-52. PubMed ID: 22289415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GATA5 CpG island hypermethylation is an independent predictor for poor clinical outcome in renal cell carcinoma.
    Peters I; Gebauer K; Dubrowinskaja N; Atschekzei F; Kramer MW; Hennenlotter J; Tezval H; Abbas M; Scherer R; Merseburger AS; Stenzl A; Kuczyk MA; Serth J
    Oncol Rep; 2014 Apr; 31(4):1523-30. PubMed ID: 24549248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant methylation of protocadherin 17 and its prognostic value in pediatric acute lymphoblastic leukemia.
    Uyen TN; Sakashita K; Al-Kzayer LF; Nakazawa Y; Kurata T; Koike K
    Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27643535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic DNA methylation markers for renal cell carcinoma: a systematic review.
    Joosten SC; Deckers IA; Aarts MJ; Hoeben A; van Roermund JG; Smits KM; Melotte V; van Engeland M; Tjan-Heijnen VC
    Epigenomics; 2017 Sep; 9(9):1243-1257. PubMed ID: 28803494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-30a-5p
    Outeiro-Pinho G; Barros-Silva D; Aznar E; Sousa AI; Vieira-Coimbra M; Oliveira J; Gonçalves CS; Costa BM; Junker K; Henrique R; Jerónimo C
    J Exp Clin Cancer Res; 2020 Jun; 39(1):98. PubMed ID: 32487203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypermethylation of the RASSF1A tumor suppressor gene in Japanese clear cell renal cell carcinoma.
    Tokinaga K; Okuda H; Nomura A; Ashida S; Furihata M; Shuin T
    Oncol Rep; 2004 Oct; 12(4):805-10. PubMed ID: 15375503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RASSF1A promoter methylation in high-grade serous ovarian cancer: A direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA.
    Giannopoulou L; Chebouti I; Pavlakis K; Kasimir-Bauer S; Lianidou ES
    Oncotarget; 2017 Mar; 8(13):21429-21443. PubMed ID: 28206954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glutathione peroxidase family and survival prognosis in patients with renal cell carcinoma.
    Li J; Huo S; Zhang R; Shi C; Sun N; Liu Q
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 May; 47(5):562-572. PubMed ID: 35753726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic and diagnostic relevance of hypermethylated in cancer 1 (HIC1) CpG island methylation in renal cell carcinoma.
    Eggers H; Steffens S; Grosshennig A; Becker JU; Hennenlotter J; Stenzl A; Merseburger AS; Kuczyk MA; Serth J
    Int J Oncol; 2012 May; 40(5):1650-8. PubMed ID: 22327210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.